FDA Approves EMCITATE (tiratricol), First Treatment for MCT8 Deficiency in the United States
核心洞察
The FDA has approved EMCITATE (tiratricol), a thyroid hormone receptor (搜索) agonist, for peripheral thyrotoxicosis (搜索) in adults and pediatric patients with MCT8 deficiency (搜索).
EMCITATE becomes the first and only FDA-approved treatment for MCT8 deficiency (搜索), also known as Allan-Herndon-Dudley syndrome (搜索), in the United States.
Approval was supported by a development program including the ReTRIACt trial, Triac Trial I and II, Erasmus Medical Center cohort and survival studies, and a U.S. expanded access program.
The U.S. Food and Drug Administration (搜索) has approved EMCITATE (tiratricol), a thyroid hormone receptor (搜索) agonist, for the treatment of peripheral thyrotoxicosis (搜索) in adults and pediatric patients with monocarboxylate transporter 8 (MCT8 (搜索)) deficiency, also known as Allan-Herndon-Dudley syndrome (搜索). Egetis Therapeutics (搜索) announced the approval on September 28, 2026. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency (搜索) in the United States.
The label carries a limitation of use: EMCITATE is not recommended for the treatment of primary hypothyroidism (搜索).
A Rare X-Linked Disorder With No Prior Approved Therapy
MCT8 deficiency (搜索) is a rare, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 (搜索) gene. These mutations impair the function of MCT8 (搜索), a cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. The result is disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. The disorder combines severe neurodevelopmental impairment with persistent peripheral thyrotoxicosis (搜索).
Elevated T3 concentrations in peripheral tissues can produce a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver, and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance, and increased susceptibility to infections. These systemic consequences of persistent thyrotoxicosis are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency (搜索) have a reported median life expectancy of approximately 35 years.
"Today marks a turning point for patients living with MCT8 deficiency (搜索) and their caregivers, who have waited long for an approved treatment in the United States. Our immediate focus is ensuring that eligible patients can access EMCITATE as quickly as possible," said Nicklas Westerholm, Chief Executive Officer of Egetis Therapeutics (搜索).
Clinical Development Program
The approval was supported by a clinical development program evaluating EMCITATE in patients with MCT8 deficiency (搜索) that included the ReTRIACt trial, Triac Trial I, Triac Trial II, the Erasmus Medical Center (EMC) Cohort Study, the EMC Survival Study, and the U.S. Expanded Access Program.
"The FDA approval of EMCITATE provides physicians in the United States with the first approved treatment option for patients and represents an important advance for the MCT8 deficiency (搜索) community," said Andrew J. Bauer, M.D., a pediatric endocrinologist and expert in thyroid hormone disorders who served as Principal Investigator in the ReTRIACt trial and Triac Trial II. Bauer also emphasized that early diagnosis is critical so that patients can be appropriately evaluated, connected with specialists, and receive coordinated multidisciplinary care.
The MCT8 (搜索)-AHDS Foundation called the approval a historic milestone for the community and an important step toward ensuring patients have access to a treatment, adding that it looks forward to continuing to advocate for expanded awareness, access, and treatment options for the worldwide MCT8 community.
Safety Profile
EMCITATE carries a boxed warning stating it is not for the treatment of obesity or for weight loss. It is contraindicated in primary hyperthyroidism (搜索).
Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, and nightmares, have occurred with EMCITATE during treatment initiation and dose titration, according to the prescribing information. The label directs clinicians to monitor and adjust the EMCITATE dose as indicated.
Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3, a laboratory test interference that clinicians should account for when interpreting thyroid hormone measurements.
The most common adverse reactions, reported in 5% or more of patients, are diarrhea, vomiting, rash, and hyperhidrosis.
Access and Commercial Launch
Egetis expects EMCITATE to be commercially available in the United States eight to ten weeks after approval. The company has established access infrastructure including specialty distribution and dedicated support resources through Egetis RareLink, its patient support program, and has partnered with PANTHERx Rare (搜索) to support medication access, education, care coordination, and ongoing treatment services.
In connection with the approval, the FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher. The company said it currently expects to explore monetization of the voucher, which could potentially occur in the fourth quarter of 2026, subject to market conditions.
EMCITATE holds marketing authorizations in the European Union and now in the United States, and is described by Egetis as the first and only approved treatment for MCT8 deficiency (搜索).